Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711237 | 1.00 | CYP2D6 (0.39) | CYP2D6LMNABLMALOX15CYP1A2 | |
| Hydrochloric Acid SCHEMBL28515119 | 0.98 | CYP2D6 (0.37) | CYP2D6LMNABLMALOX15CYP1A2 | |
| Hydrochloric Acid SCHEMBL28515120 | 0.98 | CYP2D6 (0.37) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL28626348 | 0.87 | CYP1A2 (0.36) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL26431133 | 0.82 | — | — | |
| SCHEMBL22452853 | 0.82 | — | — | |
| SCHEMBL19222961 | 0.80 | GLI1 (0.36) | SMN1; SMN2 | |
| SCHEMBL13430608 | 0.80 | CYP2D6 (0.37) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL17190116 | 0.80 | GLI1 (0.36) | SMN1; SMN2 | |
| SCHEMBL28156474 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | claimed |
| EP-3947418-B1 | PEPTIDES AND USE THEREOF | SYNTHERIX LTD (GB) | 2024-04-03 | — | — | EP | claimed |
| US-20220242914-A1 | PEPTIDES AND USE THEREOF | SYNTHERIX LIMITED (GB) | 2022-08-04 | — | — | US | claimed |
| EP-3947418-A2 | PEPTIDES AND USE THEREOF | Warenius, Hilmar M (GB) | 2022-02-09 | — | — | EP | claimed |
| WO-2020193978-A2 | PEPTIDES AND USE THEREOF | WARENIUS HILMAR (GB) | 2020-10-01 | — | — | WO | claimed |
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | disclosed |
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | disclosed |
| WO-2025081231-A1 | INHIBITORS AND USES THEREFOR | Infensa Bioscience Pty Ltd (AU) | 2025-04-24 | — | — | WO | disclosed |
| US-20240344241-A1 | PROTEINACEOUS MOLECULES AND USES THEREFOR | THE UNIVERSITY OF TOKYO (JP) | 2024-10-17 | — | — | US | disclosed |
| EP-4416282-A1 | PROTEINACEOUS MOLECULES AND USES THEREFOR | The University of Queensland (AU) | 2024-08-21 | — | — | EP | disclosed |
| EP-3947418-B1 | PEPTIDES AND USE THEREOF | SYNTHERIX LTD (GB) | 2024-04-03 | — | — | EP | disclosed |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | disclosed |
| WO-2007093012-A1 | CONOTOXIN ANALOGUES, AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE CONTAINING PEPTIDES | MONASH UNIVERSITY (AU) | 2007-08-23 | — | — | WO | disclosed |
| WO-2006127702-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006089311-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-08-17 | — | — | US | disclosed |
| US-4977260-A | Intermediates for preparing mono-, bi- and tricyclic amino acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-12-11 | — | — | US | disclosed |
| US-4849524-A | Process of preparing proline derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | disclosed |
| US-4691022-A | Process for the preparation of monocyclic, bicyclic and tricyclic aminoacids | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-09-01 | — | — | US | disclosed |
| EP-0132580-A1 | Process for the preparation of mono, bi and tricyclic aminoacids | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183745-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | CYP2D6 2008/4885LMNA 3908/4885BLM 2266/4885 |
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | NPR1, NPR3, PTMS | CYP2D6 1778/4885LMNA 716/4885BLM 2026/4885 |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIP, MMP8, SLC11A2 | CYP2D6 4718/4885LMNA 3795/4885BLM 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.